These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck. Sanz-Garcia E; Zou J; Avery L; Spreafico A; Waldron J; Goldstein D; Hansen A; Cho BCJ; de Almeida J; Hope A; Hosni A; Hahn E; Perez-Ordonez B; Zhao Z; Smith C; Zheng Y; Singaravelan N; Bratman SV; Siu LL Cell Death Differ; 2024 Apr; 31(4):460-468. PubMed ID: 38409276 [TBL] [Abstract][Full Text] [Related]
11. Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer. Muhanna N; Di Grappa MA; Chan HHL; Khan T; Jin CS; Zheng Y; Irish JC; Bratman SV Sci Rep; 2017 Dec; 7(1):16723. PubMed ID: 29196748 [TBL] [Abstract][Full Text] [Related]
12. Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG. Löck S; Linge A; Lohaus F; Ebert N; Gudziol V; Nowak A; Tinhofer I; Kalinauskaite G; Guberina M; Stuschke M; Balermpas P; von der Grün J; Grosu AL; Debus J; Ganswindt U; Belka C; Peeken JC; Combs SE; De-Colle C; Zips D; Baretton GB; Krause M; Baumann M; Radiother Oncol; 2022 Apr; 169():8-14. PubMed ID: 35182686 [TBL] [Abstract][Full Text] [Related]
13. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review. Pall AH; Jakobsen KK; Grønhøj C; von Buchwald C Acta Oncol; 2020 Jul; 59(7):845-850. PubMed ID: 32223478 [No Abstract] [Full Text] [Related]
14. A comparison between mutational profiles in tumour tissue DNA and circulating tumour DNA in head and neck squamous cell carcinoma - A systematic review. Huang X; Leo P; Jones L; Duijf PHG; Hartel G; Kenny L; Vasani S; Punyadeera C Mutat Res Rev Mutat Res; 2024; 793():108477. PubMed ID: 37977279 [TBL] [Abstract][Full Text] [Related]
15. Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. Burgener JM; Zou J; Zhao Z; Zheng Y; Shen SY; Huang SH; Keshavarzi S; Xu W; Liu FF; Liu G; Waldron JN; Weinreb I; Spreafico A; Siu LL; de Almeida JR; Goldstein DP; Hoffman MM; De Carvalho DD; Bratman SV Clin Cancer Res; 2021 Aug; 27(15):4230-4244. PubMed ID: 34158359 [TBL] [Abstract][Full Text] [Related]
16. Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma. Hanna GJ; Dennis MJ; Scarfo N; Mullin MS; Sethi RKV; Sehgal K; Annino DJ; Goguen LA; Haddad RI; Tishler RB; Margalit DN; Uppaluri R; Schoenfeld JD; Rettig EM Clin Cancer Res; 2024 Aug; 30(15):3329-3336. PubMed ID: 38824449 [TBL] [Abstract][Full Text] [Related]
17. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor. Honoré N; van der Elst A; Dietz A; van Marcke C; Helaers R; Mendola A; Dahou H; Marbaix E; Poncin R; Seront E; Schmitz S; Limaye N; Galot R; Machiels JP Eur J Cancer; 2023 Dec; 195():113372. PubMed ID: 37913682 [TBL] [Abstract][Full Text] [Related]
18. Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma. Chikuie N; Urabe Y; Ueda T; Hamamoto T; Taruya T; Kono T; Yumii K; Takeno S Sci Rep; 2022 Jun; 12(1):9316. PubMed ID: 35661138 [TBL] [Abstract][Full Text] [Related]
19. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients. van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339 [TBL] [Abstract][Full Text] [Related]